Associate Chief of Psychiatry; Joyce R. Tedlow Associate Professor of Psychiatry, Massachusetts General Hospital
Psychiatry
Dr. Jonathan E. Alpert, MD
|
|
Give Review
Jonathan Alpert is an expert in the field of Psychiatry. He went to medical school at Yale University School of Medicine. Yale University School of Medicine is a top medical college. Yale University School of Medicine has a rank of 7 in research and a 57 in primary care He received 2 awards: "Boston Magazine Top Doctors" and "America's Top Doctors". Jonathan Alpert is a published MD as well. He has 65 publications published. The latest was: Reliability and validity of the Symptoms of Depression Questionnaire (SDQ). Jonathan Alpert is registered with Medicare.
Publications
- Reliability and validity of the Symptoms of Depression Questionnaire (SDQ).
- Conditional Probability of Response or Nonresponse of Placebo Compared With Antidepressants or St John's Wort in Major Depressive Disorder.
- Simulation-based ongoing professional practice evaluation in psychiatry: a novel tool for performance assessment.
- Increased Gs? within blood cell membrane lipid microdomains in some depressive Disorders: An exploratory study.
- Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive Disorder.
- Cognitive therapy for anxious depression in STAR(â)D: What have we learned?
- SAMe and sexual functioning.
- Antidepressant effects on emotional temperament: toward a biobehavioral research paradigm for major depressive Disorder.
- Bioavailability of S-adenosyl methionine and impact on response in a randomized, double-blind, placebo-controlled trial in major depressive Disorder.
- Prevalence of MTHFR C677T and MS A2756G polymorphisms in major depressive Disorder, and their impact on response to fluoxetine treatment.
- Children of Depressed Mothers 1 Year After Remission of Maternal Depression: Findings From the STAR*D-Child Study.
- An approach to the psychopharmacologic care of patients: antidepressants, antipsychotics, anxiolytics, mood stabilizers, and natural remedies.
- S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive Disorder: a double-blind, randomized ...
- Cognitive-behavioral therapy for patients with Parkinson's disease and comorbid major depressive Disorder.
- Psychiatric OSCE performance of students with and without a previous core psychiatry clerkship.
- A double-blind, randomized controlled trial of ethyl-eicosapentaenoate for major depressive Disorder.
- Factors associated with concomitant psychotropic drug use in the treatment of Major depression: a STAR*D Report.
- Pattern of Depressive symptoms in Parkinson's disease.
- Monoamine oxidase a and catechol-o-methyltransferase functional polymorphisms and the placebo response in major depressive Disorder.
- A controlled trial of bupropion added to nicotine patch and behavioral therapy for smoking cessation in adults with unipolar depressive Disorders.
- Remission of maternal depression: relations to family functioning and youth internalizing and externalizing symptoms.
- Vagus nerve stimulation: 2-year outcomes for Bipolar versus unipolar treatment-resistant depression.
- Children of depressed mothers 1 year after the initiation of maternal treatment: findings from the STAR*D-Child Study.
- Does the duration of index episode affect the treatment outcome of major depressive Disorder? A STAR*D report.
- Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report.
- Are depressed outpatients with and without a family history of substance use Disorder different? A baseline analysis of the STAR*D cohort.
- Ethnicity/race and outcome in the treatment of depression: results from STAR*D.
- Does psychiatry residency training reflect the "real world" of psychiatry practice? A survey of residency graduates.
- Hopelessness as a predictor of non-response to fluoxetine in major depressive Disorder.
- A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment.
- Virtual reality, telemedicine, web and data processing innovations in medical and psychiatric education and clinical care.
- Predictors of relapse in a prospective study of fluoxetine treatment of Major depression.
- A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report.
- A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report.
- Somatic symptoms in outpatients with major depressive Disorder treated with fluoxetine.
- Improving depression outcome: new concepts, strategies and technologies.
- A survey of antidepressant prescribing practices in major depression with comorbid attention-deficit hyperactivity Disorder.
- Getting our own house in order: improving psychiatry education to medical students as a prelude to medical school education reform.
- Children of currently depressed mothers: a STAR*D ancillary study.
- Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive Disorder.
- Cardiovascular risk factors may moderate pharmacological treatment effects in major depressive Disorder.
- An open study of triiodothyronine augmentation of selective serotonin reuptake inhibitors in treatment-resistant major depressive Disorder.
- Outcomes of recognizing depressed Chinese American patients in primary care.
- S-adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive Disorder: an open trial following partial or nonresponse to selective serotonin reuptake in...
- Psychosocial functioning during the treatment of major depressive Disorder with fluoxetine.
- Comorbid medical illness and relapse of major depressive Disorder in the continuation phase of treatment.
- Serum cholesterol in the continuation phase of pharmacotherapy with fluoxetine in remitted major depressive Disorder.
- Serum folate, vitamin B12, and homocysteine in major depressive Disorder, Part 2: predictors of relapse during the continuation phase of pharmacotherapy.
- Serum folate, vitamin B12, and homocysteine in major depressive Disorder, Part 1: predictors of clinical response in fluoxetine-resistant depression.
- Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive Disorder.
- Somatic symptoms as predictors of time to onset of response to fluoxetine in major depressive Disorder.
- Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive Disorder.
- The impact of medical comorbidity on acute treatment in major depressive Disorder.
- S-adenosyl-methionine in depression: a comprehensive review of the literature.
- Psychiatric comorbidity as a predictor of clinical response to nortriptyline in treatment-resistant major depressive Disorder.
- Treatment-related adverse events and outcome in a clinical trial of fluoxetine for major depressive Disorder.
- Hopelessness and suicidal ideation in outpatients with treatment-resistant depression: prevalence and impact on treatment outcome.
- Lithium augmentation of nortriptyline for subjects resistant to multiple antidepressants.
- Prevention of relapse and recurrence in depression: the role of long-term pharmacotherapy and psychotherapy.
- Early-onset depression and the emotional and behavioral characteristics of offspring.
- Nortriptyline for treatment-resistant depression.
- Functioning and interpersonal relationships as predictors of response in treatment-resistant depression.
- Effects of adding cognitive therapy to fluoxetine dose increase on risk of relapse and residual depressive symptoms in continuation treatment of Major depressive disor...
- Folinic acid (Leucovorin) as an adjunctive treatment for SSRI-refractory depression.
Schools
Yale University
Chldns Hospital Harvard Med School
McLean Hospital Harvard Med School
Procedures Preformed
- Psychological Testing
- Psychotherapy and Psychophysiological Therapy (incl. Biofeedback)
Conditions Treated
- Adjustment Disorder
- Anxiety
- Attention Deficit Hyperactivity Disorder (ADHD)
- Bipolar Disorder
- View All
Doctors Specialties
- Psychiatry
Accepted Insurances
- Blue Card PPO
- BlueConnect HMO
- Blue with Managed Care Behavioral Health HMO
- Preferred Blue PPO
- Commercial Insurance Company
- Fallon Community Health Plan
- First Health (Coventry Health Care) PPO
- Choice Care PPO
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- United Healthcare
Awards
- Boston Magazine Top Doctors
- America's Top Doctors
Education
-
Boston Children's Hospital -
Yale University School of Medicine
Hospital
-
Massachusetts General Hospital
Drug Facts
| NPI NUMBER | 1508857863 | |
| NPPES Provider LastName | ALPERT | |
| NPPES Provider FirstName | JONATHAN | |
| NPPES Provider ZIPCode | 021143117 | |
| NPPES Provider State | MA | |
| Specialty Description | Psychiatry | |
| Total Claim Count | 742.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1508857863 |
| Last Name Of The Provider | ALPERT |
| First Name Of The Provider | JONATHAN |
| View All |
Similar Doctors
|
|
Dr. Nada Milosavljevic, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael C. Soule, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Daniel H. Jacobs, MD |
|
|
Dr. Jonathan L. Worth, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Oriana P. Vesga-Lopez, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Angela C. Utschig, PHD |
|
|
Dr. David C. Jimerson, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Neil Redlener, MD |
|
|
Dr. Amanda N. Fears, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Noor M. Albar, MD |
|
|
Dr. Sanjay Yadav, MD |